Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine - Eli Lilly and Company/Genentech

X
Drug Profile

Gemcitabine - Eli Lilly and Company/Genentech

Alternative Names: dFdC; dFdCTP; Gemtro; Gemzar; LY-188011

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Genentech; University of Innsbruck
  • Developer AstraZeneca; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Eli Lilly and Company; Genentech; Mayo Clinic; National Cancer Institute (USA); University of Iowa
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Phase III Cervical cancer
  • Phase II Cholangiocarcinoma; Lymphoma; Renal cell carcinoma
  • No development reported Head and neck cancer; Sarcoma; Solid tumours

Most Recent Events

  • 21 Aug 2023 Phase-II clinical trials in Cholangiocarcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT05655949)
  • 06 Jan 2020 No development reported - Phase-I/II for Sarcoma (Combination therapy, First-line therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in USA (IV) (Eli-Lilly pipeline, January 2020)
  • 06 Jan 2020 No development reported - Phase-I/II for Sarcoma (Combination therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (IV) (Eli-Lilly pipeline, January 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top